Chemokine Cxcl9 attenuates liver fibrosis-associated angiogenesis in mice
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Recent data suggest that the chemokine receptor CXCR3 is functionally involved in fibroproliferative disorders, including liver fibrosis. Neoangiogenesis is an important pathophysiological feature of liver scarring, but a functional role of angiostatic CXCR3 chemokines in this process is unclear. We therefore investigated neoangiogenesis in carbon tetrachloride (CCl4)-induced liver fibrosis in Cxcr3 −/− and wildtype mice by histological, molecular, and functional imaging methods. Furthermore, we assessed the direct role of vascular endothelial growth factor (VEGF) overexpression on liver angiogenesis and the fibroproliferative response using a Tet-inducible bitransgenic mouse model. The feasibility of attenuation of angiogenesis and associated liver fibrosis by therapeutic treatment with the angiostatic chemokine Cxcl9 was systematically analyzed in vitro and in vivo . The results demonstrate that fibrosis progression in Cxcr3 −/− mice was strongly linked to enhanced neoangiogenesis and VEGF/VEGFR2 expression compared with wildtype littermates. Systemic VEGF overexpression led to a fibrogenic response within the liver and was associated with a significantly increased Cxcl9 expression. In vitro , Cxcl9 displayed strong antiproliferative and antimigratory effects on VEGF-stimulated endothelial cells and stellate cells by way of reduced VEGFR2 (KDR), phospholipase Cγ (PLCγ), and extracellular signal-regulated kinase (ERK) phosphorylation, identifying this chemokine as a direct counter-regulatory molecule of VEGF signaling within the liver. Accordingly, systemic administration of Cxcl9 led to a strong attenuation of neoangiogenesis and experimental liver fibrosis in vivo . Conclusion: The results identify direct angiostatic and antifibrotic effects of the Cxcr3 ligand Cxcl9 in a model of experimental liver fibrosis. The amelioration of liver damage by systemic application of Cxcl9 might offer a novel therapeutic approach for chronic liver diseases associated with increased neoangiogenesis. (Hepatology 2012)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fibrotic disease and the TH1/TH2 paradigm
Wynn, T. A. (2004) · Nature Reviews Immunology · doi:10.1038/nri1412 · Cited by 1,765
Chemokines as mediators of neovascularization
Keeley, E. C., Mehrad, B., & Strieter, R. M. (2008) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.108.162925 · Cited by 192 · cited 3×
“A chemokine receptor that has been implicated in many pathophysiological processes of fibroproliferative disorders, including liver fibrosis, is CXCR3.”
BackgroundPatsenker, E., Popov, Y., Stickel, F., Schneider, V., Ledermann, M., Sägesser, H., Niedobitek, G., Goodman, S. L., & Schuppan, D. (2009) · Hepatology · doi:10.1002/hep.23144 · Cited by 174
Functional role of chemokines in liver disease models
Sahin, H., Trautwein, C., & Wasmuth, H. E. (2010) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2010.168 · Cited by 107 · cited 2×
“A chemokine receptor that has been implicated in many pathophysiological processes of fibroproliferative disorders, including liver fibrosis, is CXCR3.”
BackgroundSelf-citation
Cited by
The twilight of immunity: emerging concepts in aging of the immune system
Nikolich-Žugich, J. (2018) · Nature Immunology · doi:10.1038/s41590-017-0006-x · Cited by 1,240
Liver sinusoidal endothelial cells: Physiology and role in liver diseases
Poisson, J., Lemoinne, S., Boulanger, C., Durand, F., Moreau, R., Valla, D., & Rautou, P.-E. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2016.07.009 · Cited by 1,047
Roles for chemokines in liver disease
Marra, F., & Tacke, F. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.06.043 · Cited by 829
Evolving therapies for liver fibrosis
Schuppan, D., & Kim, Y. O. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66028 · Cited by 595
Metzemaekers, M., Vanheule, V., Janssens, R., Struyf, S., & Proost, P. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01970 · Cited by 328
Metadata
- Authors
- Sahin, H., Borkham-Kamphorst, E., Kuppe, C., Zaldivar, M. M., Grouls, C., Al-samman, M., Nellen, A., Schmitz, P., Heinrichs, D., Berres, M.-L., Doleschel, D., Scholten, D., Weiskirchen, R., Moeller, M. J., Kiessling, F., Trautwein, C., & Wasmuth, H. E.
- Venue
- Hepatology
- Published
- 2012-05
- Volume
- 55
- Issue
- 5
- Pages
- 1610-1619
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W1990780034
- Cited by
- 135
- References
- 4
- FWCI
- 7.64
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Chemokine Cxcl9 attenuates liver fibrosis-associated angiogenesis in mice. https://app.cochat.ai/papers/10.1002/hep.25545
- The paper
- Sahin, H., Borkham-Kamphorst, E., Kuppe, C., Zaldivar, M. M., Grouls, C., Al-samman, M., Nellen, A., Schmitz, P., Heinrichs, D., Berres, M.-L., Doleschel, D., Scholten, D., Weiskirchen, R., Moeller, M. J., Kiessling, F., Trautwein, C., & Wasmuth, H. E. (2012). Chemokine Cxcl9 attenuates liver fibrosis-associated angiogenesis in mice. Hepatology. https://doi.org/10.1002/hep.25545
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.